Equities Analysts Offer Predictions for YMAB FY2024 Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Stock analysts at Brookline Capital Management issued their FY2024 earnings per share estimates for Y-mAbs Therapeutics in a report issued on Wednesday, December 4th. Brookline Capital Management analyst K. Dolliver expects that the company will post earnings of ($0.75) per share for the year. Brookline Capital Management has a "Strong-Buy" rating on the stock. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.66) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics' Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($0.94) EPS.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter last year, the firm earned ($0.18) earnings per share.

Other analysts have also issued research reports about the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $20.00 target price on shares of Y-mAbs Therapeutics in a report on Monday, September 9th. Wedbush reiterated an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. Morgan Stanley dropped their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating on the stock in a report on Tuesday, August 13th. BMO Capital Markets dropped their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an "outperform" rating on the stock in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $26.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has a consensus rating of "Buy" and an average target price of $20.89.

Y-mAbs Therapeutics Trading Down 2.7 %

Shares of Y-mAbs Therapeutics stock traded down $0.28 during trading on Monday, reaching $10.26. The stock had a trading volume of 155,144 shares, compared to its average volume of 325,442. The company has a market capitalization of $459.54 million, a price-to-earnings ratio of -19.00 and a beta of 0.61. The stock has a fifty day moving average price of $13.18 and a two-hundred day moving average price of $12.75. Y-mAbs Therapeutics has a 52 week low of $6.09 and a 52 week high of $20.90.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $44,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company's stock valued at $113,000 after acquiring an additional 3,416 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $133,000. SG Americas Securities LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $178,000. Finally, Empire Financial Management Company LLC bought a new position in shares of Y-mAbs Therapeutics in the 3rd quarter valued at $210,000. 70.85% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of the company's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares in the company, valued at $877,822.57. This represents a 30.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 22.50% of the stock is currently owned by company insiders.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.